1Raimondi S, Maisonneuve P, Loweafels AB. Epidemiology of pancreatic cancer: an overview[J]. Nat Rev Gastroen- terol Hepatol,2009,6(12):699-708.
2Wolpin BM, Chan AT, Hartge P, et al. ABO blood group and the risk of pancreatic cancer[J]. J Natl Cancer Inst, 2009,101 (6):424-431.
3Winter JM, Brennan MF, Tang LH, et al. Survival after resection of pancreatic adenocarcinoma: results from a single institution over three decades[J]. Ann Surg Oncol, 2012,19(1):169-175.
4Brown JM, Giaccia AJ. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy [J]. Cancer Res,1998,58(7):1408-1416.
5Burris HA, Moore MJ, Andersen J, et al. Improvements in survival and clinical benefit with gemcitabine as first- line therapy for patients with advanced pancreas cancer: a randomized trial[J]. J Clin Onco1,1997,15(6):2403-2413.
6Neoptolemos JP. Adjuvant treatment of pancreatic cancer [J]. Eur J Cancer,2011,47(Suppl 3):S378-S380.
7Erkan M, Hausmann S, Michalski CW, et al. The role of stroma in pancreatic cancer: diagnostic and therapeutic implications[J]. Nat Rev Gastro Hepat,2012,9(8):454-467.
8Olive KP, Jacobetz MA, Davidson C J, et al. Inhibition of Hedgehog signaling enhances delivery of chemotherapy in a mouse model of pancreatic cancer[J]. Science,2009, 324(5933):1457-1461.
9Giannoni E, Bianchini F, Calorini L, et al. Cancer associa- ted fibroblasts exploit reactive oxygen species through a proinflammatory signature leading to epithelial mesenchy-mal transition and sternness[J]. Antioxid Redox Sign,2011, 14(12):2361-2371.
10Beatty GL, Chiorean EG, Fishman MP, et al. CD40 ago- nists alter tumor stroma and show efficacy against pan- creatic carcinoma in mice and humans[J]. Science,201 1, 331(6024):1612-1616.
